<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Written evidence submitted by a group of international scientists with common interests on the use of microbicidal products and possible relationship with antimicrobial resistance</title></head><body><div><p style="margin:0pt"><span style="font-family:Cambria; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:center; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Joint w</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ritten evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Jean-Yves </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Maillard</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">, Sally Bloomfield, Joana Rosado Coelho, Phillip Collier, Barry Cookson, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Séamus</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> Fanning, Philippe </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Hartemann</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">, Andrew J. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">McBain</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">, Marco </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Oggioni</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">, Herbert P. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Schweizer</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> and John </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Threlfall</span><span style="font-family:'Times New Roman'; font-size:7.33pt; font-weight:bold; vertical-align:super"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> (AMR0052)</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">This joint written evidence </span><span style="font-family:'Times New Roman'; font-size:11pt">has been </span><span style="font-family:'Times New Roman'; font-size:11pt">submitted by a</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">group of international scientists </span><span style="font-family:'Times New Roman'; font-size:11pt">with common interests on the use of microbicidal products and possible relationship with antimicrobial resistance.</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The list of the individuals from this group is listed below.</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Jean-Yves Maillard</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt">*, Sally Bloomfield</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:'Times New Roman'; font-size:11pt">, Joana Rosado Coelho</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:'Times New Roman'; font-size:11pt">, Phillip Collier</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">4</span><span style="font-family:'Times New Roman'; font-size:11pt">, Barry Cookson</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">5</span><span style="font-family:'Times New Roman'; font-size:11pt">, Séamus Fanning</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">6</span><span style="font-family:'Times New Roman'; font-size:11pt">, Philippe Hartemann</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">7</span><span style="font-family:'Times New Roman'; font-size:11pt">, Andrew J. McBain</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">8</span><span style="font-family:'Times New Roman'; font-size:11pt">, Marco Oggioni</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">9</span><span style="font-family:'Times New Roman'; font-size:11pt">, Herbert P. Schweizer</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">10</span><span style="font-family:'Times New Roman'; font-size:11pt">, John Threlfall</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">11</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt">Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK; </span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:'Times New Roman'; font-size:11pt">London School of Hygiene and Tropical Medicine, London, International Scientific Forum on Home Hygiene, UK; </span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:'Times New Roman'; font-size:11pt">INESC-ID/IST, Technical University of Lisbon, Lisbon, Portugal; </span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">4</span><span style="font-family:'Times New Roman'; font-size:11pt">School of Contemporary Sciences, University of Abertay Dundee,Dundee, UK; </span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">5</span><span style="font-family:'Times New Roman'; font-size:11pt">Division of Infection &amp; Immunity, Faculty of Medical Sciences, University College London, London, UK;</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">6</span><span style="font-family:'Times New Roman'; font-size:11pt">UCD Centres for Food Safety and Molecular Innovation &amp; Drug Design, School of Public Health, Physiotherapy &amp; Population Science, University College Dublin, Dublin 4, Ireland; </span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">7</span><span style="font-family:'Times New Roman'; font-size:11pt">Départment Environment et Santé Publique; Faculté de Médecine, Vandoeuvre-les-Nancy, France;  </span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">8</span><span style="font-family:'Times New Roman'; font-size:11pt">School of Pharmacy and Pharmaceutical </span><a name="_GoBack"><span style="font-family:'Times New Roman'; font-size:11pt">Sciences,  the University of Manchester, UK; </span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">9</span><span style="font-family:'Times New Roman'; font-size:11pt">Department of Genetics, University of Leicester;</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">10</span><span style="font-family:'Times New Roman'; font-size:11pt">Department of Microbiology, Immunology and Pathology</span></a><span style="font-family:'Times New Roman'; font-size:11pt">, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Colorado, USA;</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">12</span><span style="font-family:'Times New Roman'; font-size:11pt">Health Protection Agency, London, UK.</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Executive Summary</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The aims of the UK 5 year AMR strategy 2008-2013 are logical and commendable. Recommendations and exploration of other non-chemotherapeutic antimicrobials (hereafter referred to as microbicidal products) to prevent the spread of resistant strains are not being fully considered.</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The number of microbicidal products (i.e. products containing microbicides as defined by the Biocidal Product Regulation) and their applications has increased over the last 10 years. The EC is unable to provide data on the total amounts and types of microbicides and microbicidal products used within the European Union per year. Set against this however, in healthcare settings, usage of microbicidal products, particularly for environmental cleaning/disinfection, has declined in the last 50 or so years, apart from a few exceptions related to the control of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Clostridium difficile</span><span style="font-family:'Times New Roman'; font-size:11pt"> and methicillin-resistant </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Staphylococcus aureus </span><span style="font-family:'Times New Roman'; font-size:11pt">(MRSA).</span></p><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">It is now well accepted that not only the hands but also environmental surfaces (particularly contact surfaces) contribute significantly to the spread of infection both in hospital and out of hospital settings. By definition this means that these surfaces also contribute to the spread of AMR bacteria. Increased hand hygiene and surface decontamination compliance in healthcare settings has been linked to a decrease in infection rates. Since the routes of transmission, and the transmissibility of AMR bacteria are the same as those for non-AMR pathogens, the same control measures are appropriate to both. Measures to improve cleaning and microbicidal product compliance in both hospital and non-hospital settings and their application are needed. </span></p><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">On the other hand there is measurable evidence that exposure to microbicides can lead to reduced sensitivity to antimicrobials in microbial populations. The use of microbicides and antimicrobial resistance has been highlighted in recent European documentation. Research and investment on the impact of microbicides on emerging AMR and the spread or maintenance of AMR genetic determinants is scarce. A number of questions about the sue of microbicidal products remain unanswered:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 24.26pt; orphans:0; padding-left:4.09pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">What type of microbicides and usage applications are more/most likely to cause induction of AMR and conversely, which types of microbicides are less likely or unlikely to cause induction </span><span style="font-family:'Times New Roman'; font-size:11pt">of AMR?</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 24.26pt; orphans:0; padding-left:4.09pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">What type of microbicides and usage applications are most likely to lead to the selection of AMR in bacteria and what types are less or unlikely to lead to selection of AMR?</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 24.26pt; orphans:0; padding-left:4.09pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">What type of microbicides and usage applications are most likely to lead to the spread or maintenance of AMR genetic determinants</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 24.26pt; orphans:0; padding-left:4.09pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">To what extent and what types of microbicidal products are regularly used in the healthcare settings in the UK.</span></li></ul><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 14.2pt; text-align:justify; text-indent:-14.2pt"><span style="font-family:'Times New Roman'; font-size:11pt"> The recommendations from this group are as follows:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 24.26pt; padding-left:4.09pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The link between microbicides and AMR needs to be acknowledged.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 24.26pt; padding-left:4.09pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The importance of appropriate microbicidal product application in combating infection and preventing spread of resistant strains needs to be recognised.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 24.26pt; padding-left:4.09pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Establishing</span><span style="font-family:'Times New Roman'; font-size:11pt"> of a periodical survey surveillance networks for AMR linked to microbicides should be facilitated.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 24.26pt; padding-left:4.09pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A funding stream dedicated to microbicidal research (including application, surveillance studies) from Research Councils needs to be secured. </span><span style="font-family:'Times New Roman'; font-size:11pt">Investment is now urgently needed to optimize procedures (practices), which can be routinely used to break the chain of transmission of infectious, including AMR bacteria. This must include an evaluation of the efficacy of microbicidal products compared with detergent cleaning alone. Investment is also needed to understand the conditions leading to AMR following microbicidal product application to hands and environmental surfaces</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 24.26pt; padding-left:4.09pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Continue support of eBug project as part of the UK 5 year AMR plan.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">About this group</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">International scientists with established recognition in the field of antimicrobial resistance and microbicidal product applications</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Encompass University academics and governmental scientists</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Draw expertise in microbiology, medical and veterinary sciences</span></li></ul><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">This group of international scientists assembled because of common interests in translational issues about antimicrobial resistance (AMR) in relation to the use of microbicidal products. A publication from this group in the November 2013 Microbial Drug Resistance issue (attached), refers to the key literature, debates</span><span style="font-family:'Times New Roman'; font-size:11pt"> the increasing use of microbicides in consumer products and the raising concerns related to enhance microbicide resistance in bacteria and potential cross-resistance to </span><span style="font-family:'Times New Roman'; font-size:11pt">chemotherapeutic</span><span style="font-family:'Times New Roman'; font-size:11pt"> antimicrobials</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Reasons for submitting evidence</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="color:#ff0000; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">It is generally accepted that the leading causes of AMR relate to the use of chemotherapeutic antimicrobials and that measures to combat emerging AMR (described in the UK 5 year AMR strategy 2008-2013) have, to date, been focused on controlling such usage as well as improved infection control, discovering novel antimicrobials and improving microbial diagnosis</span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Although these aims are logical and commendable, recommendations and exploration of other non-chemotherapeutic antimicrobials to prevent the spread of resistant strains are not being fully considered. The application of infection prevention and control/hygiene measures, although referred to in the 2013-2018 AMR strategy document and other infection control documents, is not developed to their full capacity. </span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Two quite separate (and competing) aspects of the potential involvement of non-chemotherapeutic antimicrobials require consideration:</span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; list-style-position:inside; margin:0pt 0pt 0pt 38.25pt; orphans:0; text-align:justify; text-indent:-18pt; widows:0"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Whether and to what extent low level exposure to non-chemotherapeutic antimicrobials may lead to development of microbial populations which are resistant to the action of antimicrobial agents</span></li><li style="font-family:Symbol; font-size:11pt; list-style-position:inside; margin:0pt 0pt 0pt 38.25pt; orphans:0; text-align:justify; text-indent:-18pt; widows:0"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">To what extent, the appropriate use of non-chemotherapeutic antimicrobials contributes to reducing the burden of infection in the community, and thereby contribute to strategies to reduce antibiotic resistance i.e by reducing the need for antibiotic prescribing and preventing the spread of antibiotic resistant strains</span></li></ul><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The written evidence submitted by this group focuses on the non-chemotherapeutic antimicrobials.</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Factual information</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">How has antimicrobial resistance developed in the past decade?</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Microbicidal products (i.e products containing microbicides as defined by the </span><span style="font-family:'Times New Roman'; font-size:11pt">Biocidal</span><span style="font-family:'Times New Roman'; font-size:11pt"> Products Regulation; </span><a href="http://echa.europa.eu/regulations/biocidal-products-regulation"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://echa.europa.eu/regulations/biocidal-products-regulation</span></a><span style="font-family:'Times New Roman'; font-size:11pt">) are used for disinfection of surfaces, antisepsis and preservation of products</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The number of microbicidal products (and microbicides) and their applications has increased over the last 10 years, although the EC is unable to provide data on the total amounts and types of microbicides and microbicidal products used within the European Union per year.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Set against this however, in healthcare settings, usage of microbicidal products, particularly for environmental cleaning/disinfection, has declined in the last 50 or so years, apart from a few exceptions such as the use of terminal cleaning/disinfection following </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Clostridium difficile</span><span style="font-family:'Times New Roman'; font-size:11pt"> affected patient discharge from rooms and the dramatically increased use of antiseptic as a result of the methicillin-resistant </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Staphylococcus aureus</span><span style="font-family:'Times New Roman'; font-size:11pt"> target setting.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">There is measurable evidence that exposure to microbicides can lead to reduced sensitivity to antimicrobials in microbial populations. </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The use of microbicides and antimicrobial resistance have been highlighted in recent European documentation.</span></li></ul><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The main driver for antimicrobial resistance is the use and abuse of antimicrobial usage for human and animal health. This has been recognized in the past and addressed in part by interventions to promote better prescribing practice in the UK. </span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Other areas of concerns are the important use of antimicrobials for veterinary health, and the use of antimicrobials in the fermentation industry. Antimicrobial used for different applications find their way into the environment, notably into rivers, where there is evidence of high concentrations of antibiotics in effluents.</span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">There is measurable evidence that exposure to microbicides can lead to reduced sensitivity to antimicrobials in microbial populations This is to be expected, since it is well established that microbial populations routinely develop “resistance/survival” mechanisms as a result of any imposed stress e.g. heat, cold, starvation, osmotic, acidic stress, etc.  What is still lacking however is data to show whether and to what extent this might be linked to “resistance”, i.e. clinical failure of antimicrobials in treatment of infectious disease.</span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Bacteria have developed multiple mechanisms to survive antibiotic and antimicrobial exposure and the genetic determinants encoding for resistance mechanisms for some antibiotics and some microbicides can be linked and transferred between bacteria exacerbating the problems of resistance and creating a reservoir of genetic resistant determinants for the microbicides involved. </span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The number of microbicidal products and product containing a low concentration of a microbicide and the application of microbicidal products have increased tremendously in the past 10 years in response to public awareness of infection, media coverage of outbreaks of bacterial infection in healthcare and community settings and the commercial advantage to the industry to market products with an antimicrobial claim. </span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Set against this, changes in hospital disinfection policies and attitudes to disinfectants in the last 50 or so years mean that hospital usage of microbicidal products, particularly for environmental cleaning has declined in this period. However, there is no evidence that this has been associated with any decline in healthcare associated antimicrobial resistance</span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The impact of such changes in microbicide usage in healthcare and non healthcare settings has been emphasized in European documents notably from the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR 2009; “Assessment of the Antibiotic Resistance Effects of Biocides”; SCENIHR 2010: “Research strategy to address the knowledge gaps on the antimicrobial resistance effects of biocides) and Scientific Committee on Consumer Safety  (SCCS 2010:”</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Opinion on triclosan Antimicrobial Resistance”) highlighting the issue of microbicide usage and cross-resistance to antimicrobials.</span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Issues associated with microbicidal products and antimicrobial resistance were highlighted (although briefly) in the Parliamentary Office of Science and Technology Note (Oct 2013, number 446)</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What are the gaps in our knowledge about antimicrobial resistance?</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">What type of microbicides and usage applications are more/most likely to cause induction of AMR and conversely which types of microbicides are less likely or unlikely to cause induction of AMR?</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">What type of microbicides and usage applications are most likely to lead to the selection of AMR in bacteria and what types are less or unlikely to lead to selection of AMR?</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">What type of microbicides and usage applications are most likely to lead to the spread or maintenance of AMR genetic determinants</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">To what extent and what types of microbicidal products are regularly used in the healthcare settings in the UK.</span></li></ul><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Concerning microbicidal products and antimicrobial resistance, a number of EC documents from the SCENIHR (mentioned above) highlighted the lack of information of i) the induction of antimicrobial resistance following exposure to microbicidal products, ii) the selection for antimicrobial resistance in bacteria following exposure to microbicidal products and iii) the impact of microbicidal products on the dissemination of genetic determinants of resistance in bacteria notably within a complex community (biofilm, microcosm).</span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The Biocidal Product Regulation states that information on the risk of a microbicidal product to select for, or be conducive to AMR must be provided, before a microbicidal product is authorized on the European market.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified?</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">It is now well accepted that not only the hands but also environmental surfaces (particularly contact surfaces) contribute significantly to the spread of infection both in hospital and out of hospital settings. By definition this means that these surfaces also contribute to the spread of AMR bacteria.  Investment is now urgently needed to optimize procedures (practices), which can be routinely used to break the chain of transmission of infectious, including AMR bacteria. This must include an evaluation of the efficacy of microbicidal products compared with detergent cleaning alone. </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Research and investment on the impact of microbicides on emerging AMR and the spread or maintenance of AMR genetic determinants is scarce. Investment is needed to understand the conditions leading to AMR following microbicidal product application to hands and </span><span style="font-family:'Times New Roman'; font-size:11pt">environmental surfaces</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ul><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What measures (including behavioral change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens?</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Increased hand hygiene and surface decontamination compliance in healthcare settings has been linked to a decrease in infection rates</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">High hand hygiene and surface decontamination compliance in food and pharmaceutical manufacturing is linked to low product contamination</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Measures to improve cleaning and microbicidal product compliance in both hospital and non-hospital settings and their application are needed.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Since the routes of transmission, and the transmissibility of AMR bacteria are the same as those for non-AMR pathogens, the same control measures are appropriate to both.</span></li></ul><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The use of appropriate hand hygiene and increased compliance in hand hygiene (Hand Hygiene campaigns) has contributed to a decrease in infection transmission in both hospital; and non-hospital settings. This is a preventative measure.</span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The Annual Report of the Chief Medical Officer (Volume Two, 2011) on “Infections and the rise of antimicrobial resistance” states that the biggest success in the prevention of infection and antimicrobial resistance is the intervention in “controlling MRSA”. This goal had been achieved by either selected (whole body decontamination of MRSA positive patients) or generalized biocide use (whole body decontamination of all adult in-patients). </span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">There is growing evidence that surface contamination in healthcare and other settings is also linked to infection transmission.</span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">It thus follows that use of microbicidal products to reduce significantly microbial surface contamination should equally provide a reduction in infection transmission. The appropriate conditions of use, including appropriate microbicidal products and their applications, need to be better addressed to maximize efficacy while reducing the risk of AMR emerging.  This includes addressing whether and to what extent an increase in the reduction of contamination on surfaces may be achieved by the use of microbicidal products and how this might be linked to increased protection against infection exposure.</span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">There is evidence of low compliance in surface decontamination in healthcare setting; as low as 30% of surfaces are appropriately decontaminated. </span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Continued support for the Transatlantic Task Force on Antibiotic Resistance (TATFAR) is required to co-ordinate and optimize strategies.</span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The e-bug project (</span><a href="http://www.ebug.eu"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">www.ebug.eu</span></a><span style="font-family:'Times New Roman'; font-size:11pt">) was established with EU and UK financial support with the aim of ensuring that every child in Europe leaves school with an understanding of the issues related to antibiotic resistance and the basic principles of hygiene as a part of reducing the need for antibiotic prescribing and preventing spread of antibiotic resistant strains. This collaborative European project is making good progress and it is important that this project is incorporated as part of the UK 2013-2018 strategy and given adequate ongoing financial support. </span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:-14.2pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The establishment of a periodical survey (like for Antibiotic Resistance of different clinical strains of medical importance published by ECDC) surveillance networks to identify bacterial </span><span style="font-family:'Times New Roman'; font-size:11pt">susceptibility to microbicidal products used in healthcare settings and in veterinary settings. </span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:0.95pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The “UK Five Year Antimicrobial Resistance Strategy 2013 to 2018” does not mention microbicides or microbicidal products. It focuses solely on chemotherapeutic antimicrobials, novel antimicrobials, and improved diagnosis. This document does not mention in any detail, preventative measures to tackle AMR, particularly in out of hospital settings. Effective control measures in home are becoming increasingly important with more and more patients in the home e.g. following day surgery and non hospital-based treatments.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Recommendations</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Acknowledge the link between microbicides and AMR.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Recognise the importance of appropriate microbicidal product application in combating infection and preventing spread of resistant strains.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Facilitate the </span><span style="font-family:'Times New Roman'; font-size:11pt">establishment of a periodical survey surveillance networks for AMR linked to microbicides.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Ensure that a funding stream is dedicated to microbicidal research (including application, surveillance studies) from Research Councils.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Continue support of eBug project as part of the UK 5 yr AMR plan.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="margin:0pt"><span style="font-family:Cambria; font-size:12pt">&#xa0;</span></p></div></body></html>